Acyclovir/ganciclovir: no role in IM. Reduces EBV shedding in the mouth, but no clinical benefit. Ganciclovir employed by some for EBV CNS
Acyclovir and ganciclovir may reduce EBV shedding, but are ineffective clinically. Treatment of immunocompromised patients with EBV
The role of antiviral therapies in the treatment of acute and chronic EBV-associated disease is unclear. Acyclovir reduces EBV replication by inhibiting viral DNA polymerase, and studies have found that both acyclovir and the prodrug valacyclovir reduce oral shedding of EBV in patients with infectious mononucleosis.
EBV replicates during lytic infection by mechanisms common to all herpesviruses, and EBV lytic infection is inhibited by nucleoside analogues such as acyclovir
No effective antiviral therapy is available for Epstein-Barr virus (EBV) infectious mononucleosis in immunocompetent persons. Acyclovir and ganciclovir may reduce EBV shedding, but are ineffective clinically. Treatment of immunocompromised patients with EBV lymphoproliferative disease is controversial. Acyclovir has not been proven to be
No effective antiviral therapy is available for Epstein-Barr virus (EBV) infectious mononucleosis in immunocompetent persons. Acyclovir and ganciclovir may reduce EBV shedding, but are ineffective clinically. Treatment of immunocompromised patients with EBV lymphoproliferative disease is controversial. Acyclovir has not been proven to be
Thus, acyclovir combined with prednisolone inhibited oropharyngeal EBV replication without affecting duration of clinical symptoms or development of EBV
Acyclovir has no effect on infectious mononucleosis, with its value in EBV encephalitis remaining unclear.( ) EBV encephalitis is
Antiviral therapy. Acyclovir is most active in vitro against HSV, with activity against VZV being about tenfold less. Although EBV has only minimal thymidine kinase activity, EBV DNA polymerase is susceptible to inhibition by acyclovir triphosphate and thus EBV is moderately susceptible to acyclovir in vitro.
Comments